All In Biotech

Drug Trial Radar · NCT02951052

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 618 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

618

Actual

Start

Oct 28, 2016

Primary completion

May 29, 2018

Study completion Dec 31, 2029

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
Janssen Pharmaceuticals; GlaxoSmithKline
First posted
Nov 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult subjects with current viral suppression on a regimen with 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, remain suppressed upon switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). This is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, antiretroviral therapy (ART)-adult subjects who are stably suppressed on a current antiretroviral (ARV) regimen. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared with maintenance of current ARV regimen containing 2 NRTIs plus an INI, NNRTI, or a PI. Eligible subjects will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue current ART or switch to initiate oral therapy with CAB 30 mg + RPV 25 mg once daily for 4 Weeks followed by Q4 weekly (monthly) CAB LA + RPV LA injections. Following the Maintenance phase at Week 52, subjects who were randomized to continue their current ART regimen will be given an option to switch to CAB LA + RPV LA injections. Those subjects would transition to LA dosing, beginning with 4 weeks oral CAB + RPV therapy at Week 52, and receive the first IM CAB LA + RPV LA injections at Week 56.

Conditions

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Interventions

  • Cabotegravir (CAB) tabletDrug

    It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat

  • Rilpivirine (RPV) tabletDrug

    It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with "TMC" and the other side with "25". Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose

  • Cabotegravir - Injectable Suspension (CAB LA)Drug

    It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection

  • Rilpivirine - Injectable Suspension (RPV LA)Drug

    It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.

  • 2 NRTIs plus an INI, NNRTI, or PIDrug

    Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus: * INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen) * NNRTI (either the initial or second cART regimen) * Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48Time frame: Week 48

Locations

113 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Ft. Pierce, Florida

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    Vero Beach, Florida

  • GSK Investigational Site

    Macon, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Buffalo, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Chapel Hill, North Carolina

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Allentown, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Annandale, Virginia

  • GSK Investigational Site

    Lynchburg, Virginia

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma Buenos Aires, Argentina

  • GSK Investigational Site

    Rosario, Argentina

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.